Results 61 to 70 of about 6,775 (167)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Supplementary Figure S7 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells [PDF]

, 2021
Confirmation of the combination effects in cells refractory to obinutuzumab-induced direct cell death.
Yoriko Yamashita-Kashima (15088800), Natsumi Kawasaki (15088803), Yasushi Yoshimura (6553670), Shigeki Yoshiura (15088806), Naoki Harada (1822495), Takaaki Fujimura (15088797)   +5 more
core   +1 more source

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update

Internal Medicine Journal, EarlyView.
Abstract In 2023, a consensus statement on the diagnosis and management of chronic lymphocytic leukaemia (CLL) in Australasia was published. Since then, advances in clinical evidence and increased availability of molecular diagnostics and targeted therapies have further influenced contemporary CLL management.
Sean McKeague, Joanna Katarzyna Czerwinski, Xavier Badoux, Rory Bennett, Giles Best, Nicole Chia, Tara Cochrane, Kyle Crassini, Gavin Cull, Pietro Di Ciaccio, Pasquale Fedele, Rosemary Harrup, Sharon Jackson, Bryone Kuss, Masa Lasica, Denise Lee, Thomas Lew, Paula Marlton, Monique Menzies Wojtowicz, Stephen Opat, Sumita Ratnasingam, John Francis Seymour, Dipti Talaulikar, Constantine Si Lun Tam, Robert Weinkove, Joel Wight, Stephen Mulligan, Mary Ann Anderson   +27 more
wiley   +1 more source

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane [PDF]

, 2020
Obinutuzumab is thought to exert its effects through its high antibody-dependent cellular cytotoxicity (ADCC) via glyco-engineering of the Fc region. In addition, obinutuzumab causes direct binding-induced cell death (DCD) only by specifically binding to
김주영
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab

Therapeutics and Clinical Risk Management, 2015
Arpita Shah Department of Pharmacy, Georgia Regents University Medical Center, Augusta, GA, USA Abstract: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with a higher affinity for CD20 epitope, enhanced antibody-dependent
Shah A
doaj  

Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background Relapsed or refractory mantle cell lymphoma (r/r MCL) remains difficult to treat despite therapeutic advances. Methods This multicenter retrospective study included 10 patients with r/r MCL treated with glofitamab across five sites in Austria and Italy before European approval (January 2023–May 2024).
Natalia Rotter, Markus Raderer, Agnes List, Ferdinand Haslbauer, Olga Saini, Alexander Egle, Teresa Magnes, Michael Leisch, Emine Kaynak, Veronika Buxhofer‐Ausch, Beatrice Casadei, Felix Keil, Holger Rumpold, Georg Hess, Richard Greil, Pier Luigi Zinzani, Thomas Melchardt   +16 more
wiley   +1 more source

Resolution of Paraneoplastic Cutaneous Angioendotheliomatosis After CAR T‐Cell Therapy in TP53‐Deleted CLL: A Case Report

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Cutaneous manifestations of chronic lymphocytic leukemia (CLL) are heterogeneous and may result from leukemic infiltration, secondary malignancies, infectious complications, or reactive inflammatory processes. Reactive angioendotheliomatosis (RAE) is a rare vascular proliferation that has only infrequently been reported in association with ...
Feras Alfraih, Mostafa F. Mohammed Saleh, David Li, Razan Mohty, Mohamed Kharfan‐Dabaja   +4 more
wiley   +1 more source